Erbitux Related Published Studies
Well-designed clinical trials related to Erbitux (Cetuximab)
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. [2011.08.10]
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. [2011.07]
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.06.18]
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. [2011.05.20]
Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. [2011.05]
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. [2011.05]
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. [2011.03.10]
Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. [2011.01]
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. [2011.01]
Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. [2011.01]
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. [2010.12]
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. [2010.11.01]
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). [2010.10]
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. [2010.10]
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. [2010.09.20]
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. [2010.08.01]
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. [2010.08.01]
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. [2010.07.07]
Phase II Trial of FOLFOX6, Bevacizumab, and Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer. [2010.07]
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. [2010.07]
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. [2010.06]
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. [2010.04]
A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. [2010.03]
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. [2010.02.20]
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. [2010.02.20]
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. [2010.01]
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. [2010.01]
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. [2010.01]
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. [2010]
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. [2009.11]
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. [2009.10]
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. [2009.10]
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). [2009.08]
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). [2009.06]
[Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation] [2009.05.26]
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. [2009.05.02]
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. [2009.05.01]
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. [2009.04.10]
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. [2009.04.02]
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. [2009.02.10]
Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. [2009]
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. [2008.10.23]
Platinum-based chemotherapy plus cetuximab in head and neck cancer. [2008.09.11]
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. [2008.09]
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. [2008.08.05]
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. [2008.07.10]
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. [2008.07]
A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. [2008.06]
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. [2008.05.10]
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. [2008.04]
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. [2008.03]
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. [2008.02]
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. [2008.01]
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. [2007.12.20]
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. [2007.12.01]
Cetuximab for the treatment of colorectal cancer. [2007.11.15]
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. [2006.11.01]
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. [2006.06.20]
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. [2006.02.09]
Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. [2005.10.11]
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. [2004.07.22]
Well-designed clinical trials possibly related to Erbitux (Cetuximab)
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and
gemcitabine in advanced pancreatic cancer patients. [2014]
Afatinib versus placebo as adjuvant therapy after chemoradiation in a
double-blind, phase III study (LUX-Head & Neck 2) in patients with primary
unresected, clinically intermediate-to-high-risk head and neck cancer: study
protocol for a randomized controlled trial. [2014]
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. [2011.07.12]
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. [2011.07]
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. [2011.06.29]
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. [2011.04]
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. [2011.02]
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. [2011.01]
Predictive biomarker validation in practice: lessons from real trials. [2010.10]
Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. [2010.10]
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. [2010.07]
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. [2010.03]
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). [2010]
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. [2009.12.01]
Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design. [2009.10.23]
Lessons learned from independent central review. [2009.01]
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). [2008.08.15]
Advances in chemotherapy against advanced or metastatic colorectal cancer. [2008]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.06.01]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.04.11]
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. [2006.05]
An overview of eastern cooperative oncology group stage III non-small cell lung cancer studies. [2005.04]
Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. [2004.10]
Integration of novel agents in the treatment of colorectal cancer. [2004.09]
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. [2002.02]
Other research related to Erbitux (Cetuximab)
Left-sided primary tumors are associated with favorable prognosis in patients
with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with
cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. [2014]
Intermittent chemotherapy plus either intermittent or continuous cetuximab for
first-line treatment of patients with KRAS wild-type advanced colorectal cancer
(COIN-B): a randomised phase 2 trial. [2014]
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized
phase II trial of sequential or concurrent cetuximab and pemetrexed in previously
treated non-small cell lung cancer. [2014]
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of
advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. [2014]
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in
patients with advanced cancer. [2014]
A randomised, open-label phase II trial of afatinib versus cetuximab in patients
with metastatic colorectal cancer. [2014]
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive
advanced non-small cell lung cancer. [2014]
EGFR expression and survival in patients given cetuximab and chemoradiation for
stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. [2014]
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell
carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. [2014]
Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced
non-small cell lung carcinoma: efficacy and safety outcomes of a randomized,
multi-center phase II study investigating. [2014]
Phase II open-label study to assess efficacy and safety of lenalidomide in
combination with cetuximab in KRAS-mutant metastatic colorectal cancer. [2013]
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive
non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label,
randomised trial. [2013]
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus
cetuximab in patients with advanced colorectal cancer. [2013]
Treatment related severe and fatal adverse events with cetuximab in colorectal
cancer patients: a meta-analysis. [2013]
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with
metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a
randomised Phase 2 study. [2013]
|